The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2026
Comparative effectiveness of antiviral therapy according to immune status among pregnant women with chronic hepatitis B virus infection: a retrospective cohort study.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhu Lin, Jia Jia, Yu Wenjing, Han Guorong
Аннотация
PURPOSE: This study evaluates phase-specific antiviral efficacy of tenofovir disoproxil fumarate (TDF) in pregnant women with hepatitis B virus (HBV) infection, comparing immune-tolerant (IT), inactive carrier (IC), and their corresponding gray zone (GZ-A, GZ-C). Perinatal outcomes and mother-to-child transmission (MTCT) risks were also assessed across these phases.
METHODS: In this retrospective study, 717 pregnant women with HBV infection from Nanjing, China (2021-2023) were stratified into IT (n = 317), IC (n = 76), GZ-A (n = 98), and GZ-C (n = 226). Among them, 365 women received TDF antiviral therapy during mid-to-late pregnancy. Primary endpoints included complete virological response rate (CVR) and reductions in HBV DNA and HBsAg from baseline, measured at delivery and 6 months postpartum.
RESULTS: TDF significantly reduced HBV DNA levels across all groups (p < .001), with the highest CVR rate observed in GZ-A (41.94% vs. 15.88% in IT at 6 months postpartum, p = .002). Despite higher rates of transient liver dysfunction in GZ-A (22.45% vs. 12.62% in IT, p = .007), no group exhibited increased MTCT or adverse pregnancy outcomes (APOs, p > .05). HBsAg decline was most pronounced in GZ-C at 6 months postpartum (Δ = 0.69 log10 IU/mL vs Δ = 0.47 log10 IU/mL in IC, p < .01).
CONCLUSION: TDF effectively suppresses viral replication in pregnant women with HBV infection, including historically undertreated GZ subgroups, without compromising pregnancy safety. These findings provide a reference for phase-specific management strategies to optimize perinatal HBV care.
METHODS: In this retrospective study, 717 pregnant women with HBV infection from Nanjing, China (2021-2023) were stratified into IT (n = 317), IC (n = 76), GZ-A (n = 98), and GZ-C (n = 226). Among them, 365 women received TDF antiviral therapy during mid-to-late pregnancy. Primary endpoints included complete virological response rate (CVR) and reductions in HBV DNA and HBsAg from baseline, measured at delivery and 6 months postpartum.
RESULTS: TDF significantly reduced HBV DNA levels across all groups (p < .001), with the highest CVR rate observed in GZ-A (41.94% vs. 15.88% in IT at 6 months postpartum, p = .002). Despite higher rates of transient liver dysfunction in GZ-A (22.45% vs. 12.62% in IT, p = .007), no group exhibited increased MTCT or adverse pregnancy outcomes (APOs, p > .05). HBsAg decline was most pronounced in GZ-C at 6 months postpartum (Δ = 0.69 log10 IU/mL vs Δ = 0.47 log10 IU/mL in IC, p < .01).
CONCLUSION: TDF effectively suppresses viral replication in pregnant women with HBV infection, including historically undertreated GZ subgroups, without compromising pregnancy safety. These findings provide a reference for phase-specific management strategies to optimize perinatal HBV care.